肝康Ⅱ号对乙型肝炎肝硬化患者血浆硫化氢和一氧化氮水平的影响

doi:10.3969/j.issn.1672-5069.2012.01.008

Abstract

Abstract: Objective To observe the change of Gankang No.Ⅱon the hydrogen sulfide（H2S）and nitric oxide（NO）levels in patients with hepatitis B liver cirrhosis.Methods 64 patients with hepatitis B liver cirrhosis were randomly assigned to treatment group and control group.The treatment group was treated with Gankang No.Ⅱ in addition to routine treatment.Results After treatment,H2S and NO levels in treatment group were 22.12±3.12μmmol/L and 44.78±5.12μmmol/L,significantly different from those in control group（19.01±2.98μmmol/L and 49.23±3.97μmmol/L,respectively）;After treatment,the TBIL,ALT,ALB and PTA in treatment group were improved（P<0.01）.Conclusion Gankang No.Ⅱ can modulate the H2S and NO level in patients with liver cirrhosis.

Key words: Hepatitis B, Liver Cirrhosis, Gankang No.Ⅱ, Hydrogen sulfide, Nitric oxide

Li Fang, Lei Feifei, Tan Huabing, et al. The effects of Gankang No.Ⅱ on serum hydrogen sulfide and nitric oxide levels in patients with hepatitis B liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(1): 23-23.

References

[1] 占国清,邓文钦,李金科,等. 肝康Ⅱ号治疗慢性乙型肝炎肝纤维化的临床观察. 临床肝胆病杂志,2006,22（5）:328-329.
[2] 占国清,邓文钦,李金科,等. 肝康Ⅱ号抗肝纤维化的实验研究. 中国中西医结合杂志,2006,14（6S1）: 63-66.
[3] 邓文钦,李金科,李红,等. 肝康Ⅱ号联合促肝细胞生长素治疗慢性重型肝炎的临床观察. 中国中西医结合杂志,2003,23（5）: 392-393.
[4] 谭华炳,李刚,胡波,等. 肝康Ⅱ号联合血浆置换治疗慢性肝衰竭临床分析. 中国中医急症杂志,2011,20（8）:1223-1225.
[5] 张宁,郑勇,王于理,等. 内源性硫化氢在不同时期大鼠肝硬化中的作用. 世界华人消化杂志,2009,17（3）:307-311.
[6] 张艳,张伟. 气体信号分子硫化氢在肝硬化患者中的表达和意义. 河北医学,2009,5（6）:649-651.
[7] 谭华炳,李金科. 气体信号分子硫化氢与肝硬化关系研究进展. 西南国防医药杂志,2011,21（1）:109-110.
[8] 中华医学会传染病与寄生虫学分会、肝病学分会. 病毒性肝炎防治方案. 中华传染病杂志,2001,19（1）:56-62.
[9] 谭华炳,张继红,李龙霞. 当代内科理论与实践（消化分册）. 北京:中国科学技术出版社,2011:260-262.
[10] Zhang CY,Du JB,Bu DF,et al. The regulatory effect of hydrogen sulfide on hypoxic pulmonary hypertension in rats. Biochem Biophys Res Commun,2003,302:810-816.
[11] Truong DH,Mihajlovic A,Gunness P,et al. Prevention of hydrogen sulfide（H2S）-induced mouse lethality and cytotoxicity by hydroxocobalamin （vitamin B（12a）.Toxicology,2007,242:16-22.
[12] Fiorucci S,Antonelli E,Mencarelli A,et al. The third gas:H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. Hepatology,2005,42:539-548.
[13] Bhimani EK,Serracino-Inglott F,Sarela AI,et al.Hepatic and mesenteric nitric oxide synthase expression in a rat model of CCl（4）-induced cirrhosis. J Surg Res,2003,113（1）:172-178.
[14] Koeppel TA,Mihaljevic N,Kraenzlin B,et al. Enhanced iNOS gene expression in the steatotic rat liver after normothermic ischemia. Eur Surg Res,2007,39（5）:303-311.
[15] Garcia-Ruiz I,Rodriguez-Juan C,Diaz-Sanjuan T,et al. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology,2006,44（3）:581-591.
[16] Carmiel-Haggai M,Cederbaum AI,Nieto N. Binge ethanol exposure increases liver injury in obese rats. Gastroenterology,2003,125（6）:1818-1833.
[17] 夏宣平,倪莉,施正超,等. 肝硬化患者血一氧化氮和内皮素-1的变化及其临床意义. 实用医学杂志,2009,25（7）:1063-1064.
[18] 宋丽秀,郑勇,陈卫刚,等. 大鼠肝硬化形成中气体信号分子一氧化氮、一氧化碳对硫化氢/胱硫醚-γ-裂解酶体系的影响. 现代生物医学进展,2010,10（7）:1213-1216.
[19] Zou ZM,Xu LZ,Yang SL. HPLC fingerprinting of total glucosides of paeonyn. Acta Pharm Sin,2003,38（1）:46-49.
[20] 阮金兰,赵钟祥,曾庆忠,等. 赤芍化学成分和药理作用的研究进展.中国药理学通报,2003,19（9）:965-970.
[21] 罗琳,窦志华,吴锋,等. 赤芍总苷退黄降酶的作用及机制研究.中国现代应用药学,2010,27（4）:285-288.

The effects of Gankang No.Ⅱ on serum hydrogen sulfide and nitric oxide levels in patients with hepatitis B liver cirrhosis

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[3]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[4]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[5]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[6]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[7]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[8]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[9]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[10]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[11]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[12]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[13]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[14]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[15]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.